CryoPort’s Stabilization Amid Market Uncertainties: A Hold Rating Analysis

Leerink Partners analyst Puneet Souda maintained a Hold rating on CryoPort (CYRX – Research Report) on March 4 and set a price target of $12.00.

Puneet Souda has given his Hold rating due to a combination of factors impacting CryoPort’s current and future performance. The company reported a slight revenue beat in the fourth quarter of 2024, primarily driven by stabilization in their MVE product line. This stabilization comes after two years of significant declines, which management has noted as a positive sign for recovery. However, the services segment underperformed expectations, although there was notable growth in the commercial CGT sector.
Looking ahead to 2025, CryoPort’s management has provided guidance that aligns with consensus expectations, driven by anticipated growth in services and commercial products. Despite these positive indicators, there are significant uncertainties in the healthcare market, including potential risks from tariffs, geopolitical tensions with China, and changes at regulatory bodies like the FDA and NIH. These factors contribute to the cautious outlook, leading to the Hold rating, as the company has historically met the lower end of its guidance even after reductions.

In another report released on March 5, Jefferies also maintained a Hold rating on the stock with a $6.50 price target.

CYRX’s price has also changed dramatically for the past six months – from $8.560 to $5.060, which is a -40.89% drop .